Thermo Fisher Scientific 8-K
PositiveDeal completed
Clario acquisition closes, adding clinical-trial endpoint data capabilities to Laboratory Products and Biopharma Services.
Filed 2026-03-24 08:02 ET
- 8.01 Other Events
- 9.01 Financial Statements and Exhibits
Summary
Thermo Fisher completed its acquisition of Clario Holdings, a provider of clinical-trial endpoint data solutions. Clario joins Thermo Fisher’s Laboratory Products and Biopharma Services segment; the company cited Clario’s complementary clinical research capabilities and expects a double-digit internal rate of return.
Key Figures
- Purchase price: $8.875B in cash at closing, plus $125M payable in January 2027 and up to $400M in earn-out payments tied to Clario’s 2026 and 2027 performance.
- Clario’s platform has supported ≈70% of FDA and EMA novel drug approvals over the past decade.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Clario business growth | — | High single digits | — | — |
| Adjusted EPS contribution | First year after close | $0.45 | — | — |
| Adjusted operating income synergies | Year 5 after close | ≈$175M | — | Reaffirmed |
Investor Takeaways
- Thermo Fisher plans to provide details on the acquisition’s impact on its 2026 financials at its upcoming Q1 earnings call.
- Integration progress and whether the company realizes the expected synergies will affect the stated return profile.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3